A Study to Evaluate Safety, Tolerability, and Efficacy of Eteplirsen in Patients With Duchenne Muscular Dystrophy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03985878|
Recruitment Status : Not yet recruiting
First Posted : June 14, 2019
Last Update Posted : June 14, 2019
|Condition or disease||Intervention/treatment||Phase|
|Duchenne Muscular Dystrophy||Drug: Eteplirsen||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||15 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||An Open-Label Safety, Tolerability, and Efficacy Study of Eteplirsen in Patients With Duchenne Muscular Dystrophy Who Have Completed Study 4658-102|
|Estimated Study Start Date :||June 19, 2019|
|Estimated Primary Completion Date :||November 2026|
|Estimated Study Completion Date :||February 2027|
Patients will receive eteplirsen via intravenous (IV) infusions, once weekly, for up to 284 weeks.
Eteplirsen IV infusion once weekly.
- Incidence of Adverse Events (AEs) [ Time Frame: Up to 288 weeks ]
- Incidence of Death Due to Adverse Events [ Time Frame: Up to 288 weeks ]
- Incidence of Adverse Events of Special Interest (AESIs) [ Time Frame: Up to 288 weeks ]AESIs will be defined as any AE that is of scientific and medical concern specific to study treatment, for which ongoing and rapid communication by the Investigator to the sponsor is appropriate. AESIs will include infusion-related reactions, hypersensitivity, and renal events.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03985878
|Contact: Medical Information||+1 email@example.com|
|Study Director:||Medical Director||Sarepta Therapeutics, Inc.|